The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Sounding Board
PreviousPrevious
Volume 334:984-986 April 11, 1996 Number 15
NextNext

Olestra and the FDA

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Olestra, a polyester of sucrose and six or more triglycerides, was approved by the Food and Drug Administration (FDA) on January 24 as a nondigestible substitute for fat in snack foods, after a long review of the petition from its manufacturer, Procter & Gamble. Procter & Gamble's patent on Olestra, extended by an act of Congress in 1994, was due to expire on January 25.

Olestra is a technical novelty. Unfortunately, there is almost no relevant scientific literature on its potential health effects, except for studies conducted by Procter & Gamble. Many experts believe that neither the purported benefit of . . . [Full Text of this Article]


Related Letters:

Olestra and the FDA
Kleinman R. E., Schneeman B., Manning W. J., Stampfer M. J., Willett W. C., Karstadt M., Jacobson M. F., Blackburn H.
Extract | Full Text  
N Engl J Med 1996; 335:668-670, Aug 29, 1996. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.